German COVID-19 vaccine developer looks to raise up to $213 mln in US IPO
By REUTERS
German biotech CureVac B.V., which is in early stages of testing its coronavirus vaccine, said on Monday it expects to raise up to $213 million in its U.S. initial public offering (IPO).CureVac said it expects its offering of 13.33 million shares to be priced between $14.00 and $16.00 per share.War Cabinet meeting cancelled - report
